Samjo Management LLC Invests $2.02 Million in Certara, Inc. (NASDAQ:CERT)

Samjo Management LLC acquired a new stake in shares of Certara, Inc. (NASDAQ:CERT) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 190,000 shares of the company’s stock, valued at approximately $2,024,000. Samjo Management LLC owned approximately 0.12% of Certara at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Venturi Wealth Management LLC raised its holdings in shares of Certara by 839.1% in the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock valued at $30,000 after acquiring an additional 2,509 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of Certara by 48.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company’s stock worth $34,000 after purchasing an additional 1,047 shares during the period. Blue Trust Inc. boosted its stake in shares of Certara by 20.9% during the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock valued at $56,000 after purchasing an additional 822 shares in the last quarter. ANTIPODES PARTNERS Ltd increased its holdings in Certara by 204.7% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 5,442 shares of the company’s stock valued at $58,000 after buying an additional 3,656 shares during the period. Finally, KBC Group NV raised its stake in Certara by 64.1% in the fourth quarter. KBC Group NV now owns 7,998 shares of the company’s stock worth $85,000 after buying an additional 3,125 shares in the last quarter. 73.96% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

CERT has been the topic of several recent research reports. TD Cowen started coverage on Certara in a research report on Thursday, February 27th. They set a “buy” rating and a $16.00 target price on the stock. Barclays increased their price objective on Certara from $12.00 to $13.00 and gave the company an “equal weight” rating in a report on Friday, February 28th. Stephens reissued an “overweight” rating and set a $17.00 target price on shares of Certara in a research report on Thursday, February 27th. Finally, William Blair reissued a “market perform” rating on shares of Certara in a report on Thursday, February 27th. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $15.83.

Certara Trading Down 2.4 %

Shares of Certara stock opened at $9.55 on Friday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. Certara, Inc. has a fifty-two week low of $9.21 and a fifty-two week high of $19.18. The firm has a 50-day simple moving average of $12.14 and a two-hundred day simple moving average of $11.41. The company has a market cap of $1.54 billion, a P/E ratio of -47.75, a price-to-earnings-growth ratio of 9.29 and a beta of 1.64.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.